Personalized Medicine
Cell & gene therapy, diagnostics and precision care.
Latest Personalized Medicine news
Ultragenyx Receives Accelerated FDA Approval For Metabolic Gene Therapy
Read at Inside Precision Medicine →The New Era of Pharma Distribution: Balancing Precision and Scale
Read at Pharmaceutical Commerce →CGT Global Convergence 2026: India must bridge innovation and patient access, says Ravi Boratakar
Read at BioSpectrum India →CGT Global Convergence 2026: India charts roadmap from scientific innovation to patient access
Read at BioSpectrum India →Spatial biology in cell & gene therapy
Read at Drug Discovery News →From the knowledge base
What did we learn from Big Pharma’s Q2 results?
Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.
Regulatory tracker: J&J scores EU approval for Tecvayli-Darzalex combo
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
The Oral GLP-1 Tracker: Novo's Wegovy pill back on track as Lilly's momentum slows
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
Lundbeck continues neuroscience evolution as CEO keeps company ‘punching above its weight’
Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the nature of the incident for now.
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your heard-earned discoveries, but the immuno-oncology startup is so far sticking to its transparent approach.